Curcumin and nano‐curcumin applications in psychiatric disorders

Psychiatric disorders cause long‐lasting disabilities across different age groups. While various medications are available for mental disorders, some patients do not fully benefit from them or experience treatment resistance. The pathogenesis of psychiatric disorders involves multiple mechanisms, in...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research Vol. 38; no. 8; pp. 4240 - 4260
Main Authors: Mohammadzadeh, R., Fathi, M., Pourseif, M. M., Omidi, Y., Farhang, S., Barzegar Jalali, M., Valizadeh, H., Nakhlband, A., Adibkia, K.
Format: Journal Article
Language:English
Published: Chichester, UK John Wiley & Sons, Ltd 01.08.2024
Wiley Subscription Services, Inc
Subjects:
Animals
Antidepressants
Antidepressive Agents - pharmacology
Antidepressive Agents - therapeutic use
anxiety
Anxiety disorders
Anxiety Disorders - drug therapy
Bipolar disorder
Bipolar Disorder - drug therapy
Clinical trials
Curcumin
Curcumin - chemistry
Curcumin - pharmacology
Curcumin - therapeutic use
Depressive Disorder, Major - drug therapy
Dosage
Effectiveness
Humans
inflammation
Inflammatory response
Liposomes - chemistry
Mental depression
Mental disorders
Mental Disorders - drug therapy
nanocurcumin
Nanoparticles
Nanoparticles - chemistry
Neuroprotection
Pathogenesis
phytotherapy
psychiatric disorders
Schizophrenia
Schizophrenia - drug therapy
Treatment resistance
nanocurcumin
curcumin
psychiatric disorders
ISSN:0951-418X, 1099-1573, 1099-1573
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Psychiatric disorders cause long‐lasting disabilities across different age groups. While various medications are available for mental disorders, some patients do not fully benefit from them or experience treatment resistance. The pathogenesis of psychiatric disorders involves multiple mechanisms, including an increase in the inflammatory response. Targeting inflammatory mechanisms has shown promise as a therapeutic approach for these disorders. Curcumin, known for its anti‐inflammatory properties and potential neuroprotective effects, has been the subject of studies investigating its potential as a treatment option for psychiatric disorders. This review comprehensively examines the potential therapeutic role of curcumin and its nanoformulations in psychiatric conditions, including major depressive disorder (MDD), bipolar disorder, schizophrenia, and anxiety disorders. There is lack of robust clinical trials across all the studied psychiatric disorders, particularly bipolar disorder and schizophrenia. More studies have focused on MDD. Studies on depression indicate that curcumin may be effective as an antidepressant agent, either alone or as an adjunct therapy. However, inconsistencies exist among study findings, highlighting the need for further research with improved blinding, optimized dosages, and treatment durations. Limited evidence supports the use of curcumin for bipolar disorder, making its therapeutic application challenging. Well‐designed clinical trials are warranted to explore its potential therapeutic benefits. Exploring various formulations and delivery strategies, such as utilizing liposomes and nanoparticles, presents intriguing avenues for future research. More extensive clinical trials are needed to assess the efficacy of curcumin as a standalone or adjunctive treatment for psychiatric disorders, focusing on optimal dosages, formulations, and treatment durations. Curcumin and nano‐curcumin applications for psychiatric disorders.
AbstractList Psychiatric disorders cause long-lasting disabilities across different age groups. While various medications are available for mental disorders, some patients do not fully benefit from them or experience treatment resistance. The pathogenesis of psychiatric disorders involves multiple mechanisms, including an increase in the inflammatory response. Targeting inflammatory mechanisms has shown promise as a therapeutic approach for these disorders. Curcumin, known for its anti-inflammatory properties and potential neuroprotective effects, has been the subject of studies investigating its potential as a treatment option for psychiatric disorders. This review comprehensively examines the potential therapeutic role of curcumin and its nanoformulations in psychiatric conditions, including major depressive disorder (MDD), bipolar disorder, schizophrenia, and anxiety disorders. There is lack of robust clinical trials across all the studied psychiatric disorders, particularly bipolar disorder and schizophrenia. More studies have focused on MDD. Studies on depression indicate that curcumin may be effective as an antidepressant agent, either alone or as an adjunct therapy. However, inconsistencies exist among study findings, highlighting the need for further research with improved blinding, optimized dosages, and treatment durations. Limited evidence supports the use of curcumin for bipolar disorder, making its therapeutic application challenging. Well-designed clinical trials are warranted to explore its potential therapeutic benefits. Exploring various formulations and delivery strategies, such as utilizing liposomes and nanoparticles, presents intriguing avenues for future research. More extensive clinical trials are needed to assess the efficacy of curcumin as a standalone or adjunctive treatment for psychiatric disorders, focusing on optimal dosages, formulations, and treatment durations.Psychiatric disorders cause long-lasting disabilities across different age groups. While various medications are available for mental disorders, some patients do not fully benefit from them or experience treatment resistance. The pathogenesis of psychiatric disorders involves multiple mechanisms, including an increase in the inflammatory response. Targeting inflammatory mechanisms has shown promise as a therapeutic approach for these disorders. Curcumin, known for its anti-inflammatory properties and potential neuroprotective effects, has been the subject of studies investigating its potential as a treatment option for psychiatric disorders. This review comprehensively examines the potential therapeutic role of curcumin and its nanoformulations in psychiatric conditions, including major depressive disorder (MDD), bipolar disorder, schizophrenia, and anxiety disorders. There is lack of robust clinical trials across all the studied psychiatric disorders, particularly bipolar disorder and schizophrenia. More studies have focused on MDD. Studies on depression indicate that curcumin may be effective as an antidepressant agent, either alone or as an adjunct therapy. However, inconsistencies exist among study findings, highlighting the need for further research with improved blinding, optimized dosages, and treatment durations. Limited evidence supports the use of curcumin for bipolar disorder, making its therapeutic application challenging. Well-designed clinical trials are warranted to explore its potential therapeutic benefits. Exploring various formulations and delivery strategies, such as utilizing liposomes and nanoparticles, presents intriguing avenues for future research. More extensive clinical trials are needed to assess the efficacy of curcumin as a standalone or adjunctive treatment for psychiatric disorders, focusing on optimal dosages, formulations, and treatment durations.
Psychiatric disorders cause long‐lasting disabilities across different age groups. While various medications are available for mental disorders, some patients do not fully benefit from them or experience treatment resistance. The pathogenesis of psychiatric disorders involves multiple mechanisms, including an increase in the inflammatory response. Targeting inflammatory mechanisms has shown promise as a therapeutic approach for these disorders. Curcumin, known for its anti‐inflammatory properties and potential neuroprotective effects, has been the subject of studies investigating its potential as a treatment option for psychiatric disorders. This review comprehensively examines the potential therapeutic role of curcumin and its nanoformulations in psychiatric conditions, including major depressive disorder (MDD), bipolar disorder, schizophrenia, and anxiety disorders. There is lack of robust clinical trials across all the studied psychiatric disorders, particularly bipolar disorder and schizophrenia. More studies have focused on MDD. Studies on depression indicate that curcumin may be effective as an antidepressant agent, either alone or as an adjunct therapy. However, inconsistencies exist among study findings, highlighting the need for further research with improved blinding, optimized dosages, and treatment durations. Limited evidence supports the use of curcumin for bipolar disorder, making its therapeutic application challenging. Well‐designed clinical trials are warranted to explore its potential therapeutic benefits. Exploring various formulations and delivery strategies, such as utilizing liposomes and nanoparticles, presents intriguing avenues for future research. More extensive clinical trials are needed to assess the efficacy of curcumin as a standalone or adjunctive treatment for psychiatric disorders, focusing on optimal dosages, formulations, and treatment durations.
Psychiatric disorders cause long‐lasting disabilities across different age groups. While various medications are available for mental disorders, some patients do not fully benefit from them or experience treatment resistance. The pathogenesis of psychiatric disorders involves multiple mechanisms, including an increase in the inflammatory response. Targeting inflammatory mechanisms has shown promise as a therapeutic approach for these disorders. Curcumin, known for its anti‐inflammatory properties and potential neuroprotective effects, has been the subject of studies investigating its potential as a treatment option for psychiatric disorders. This review comprehensively examines the potential therapeutic role of curcumin and its nanoformulations in psychiatric conditions, including major depressive disorder (MDD), bipolar disorder, schizophrenia, and anxiety disorders. There is lack of robust clinical trials across all the studied psychiatric disorders, particularly bipolar disorder and schizophrenia. More studies have focused on MDD. Studies on depression indicate that curcumin may be effective as an antidepressant agent, either alone or as an adjunct therapy. However, inconsistencies exist among study findings, highlighting the need for further research with improved blinding, optimized dosages, and treatment durations. Limited evidence supports the use of curcumin for bipolar disorder, making its therapeutic application challenging. Well‐designed clinical trials are warranted to explore its potential therapeutic benefits. Exploring various formulations and delivery strategies, such as utilizing liposomes and nanoparticles, presents intriguing avenues for future research. More extensive clinical trials are needed to assess the efficacy of curcumin as a standalone or adjunctive treatment for psychiatric disorders, focusing on optimal dosages, formulations, and treatment durations. Curcumin and nano‐curcumin applications for psychiatric disorders.
Author Fathi, M.
Nakhlband, A.
Omidi, Y.
Valizadeh, H.
Adibkia, K.
Barzegar Jalali, M.
Pourseif, M. M.
Farhang, S.
Mohammadzadeh, R.
Author_xml – sequence: 1
  givenname: R.
  orcidid: 0000-0002-5001-2953
  surname: Mohammadzadeh
  fullname: Mohammadzadeh, R.
  organization: Tabriz University of Medical Sciences
– sequence: 2
  givenname: M.
  surname: Fathi
  fullname: Fathi, M.
  organization: Tabriz University of Medical Sciences
– sequence: 3
  givenname: M. M.
  surname: Pourseif
  fullname: Pourseif, M. M.
  organization: Tabriz University of Medical Sciences
– sequence: 4
  givenname: Y.
  surname: Omidi
  fullname: Omidi, Y.
  organization: College of Pharmacy, Nova Southeastern University
– sequence: 5
  givenname: S.
  surname: Farhang
  fullname: Farhang, S.
  organization: Tabriz University of Medical Sciences
– sequence: 6
  givenname: M.
  surname: Barzegar Jalali
  fullname: Barzegar Jalali, M.
  organization: Tabriz University of Medical Sciences
– sequence: 7
  givenname: H.
  surname: Valizadeh
  fullname: Valizadeh, H.
  organization: Tabriz University of Medical Sciences
– sequence: 8
  givenname: A.
  orcidid: 0000-0002-4883-6902
  surname: Nakhlband
  fullname: Nakhlband, A.
  email: ailarnakhlband@yahoo.com, nakhlbanda@tbzmed.ac.ir
  organization: Tabriz University of Medical Sciences
– sequence: 9
  givenname: K.
  surname: Adibkia
  fullname: Adibkia, K.
  email: adibkia@tbzmed.ac.ir
  organization: Tabriz University of Medical Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38965868$$D View this record in MEDLINE/PubMed
BookMark eNqF0ctKxDAUBuAgI85FwSeQghs3HXNp0mSpgzcYUGQEdyVNU8zQpjVpkdn5CD6jT2Ln4giD4iokfOeEc_4h6NnKagCOERwjCPF53bgxx4zugQGCQoSIxqQHBlBQFEaIP_fB0Ps5hFBgGB2APuGCUc74AFxOWqfa0thA2iyw0laf7x9q-1bXhVGyMZX1QXev_UK9GNk4o4LM-Mpl2vlDsJ_LwuujzTkCT9dXs8ltOL2_uZtcTENFOKYhRlxJERFJ4pzjXOgMZSzDLEs1iXEaSZjzPI1phDFjMeVcExVBKliKUq2gJCNwtu5bu-q11b5JSuOVLgppddX6hCDaNRKQo_8pjBlEIhaso6c7dF61znaDdEpgLCIe406dbFSbljpLamdK6RbJ9yJ_flSu8t7pfEsQTJYZJV1GyTKjjo53qDLNaseNk6b4rSBcF7yZQi_-bJw8zB5X_gtaFaGO
CitedBy_id crossref_primary_10_1016_j_foodchem_2025_144721
crossref_primary_10_1016_j_intimp_2025_114910
crossref_primary_10_1016_j_jpha_2025_101341
crossref_primary_10_1016_j_neurot_2025_e00600
crossref_primary_10_1111_cote_12835
crossref_primary_10_1007_s40473_025_00303_3
Cites_doi 10.1007/978-981-19-7376-5_7
10.2174/1389450123666220922094403
10.1017/S0033291719001454
10.1002/ptr.5998
10.1016/j.bbr.2012.10.049
10.1007/s10753-023-01795-5
10.3233/HAB-2010-0229
10.1111/cns.13569
10.1016/B978-0-12-374947-5.00060-2
10.1016/j.heliyon.2020.e04482
10.1038/s41380-021-01200-3
10.2174/1871527315666161122144659
10.1166/jbns.2018.1524
10.1016/j.nbd.2009.11.010
10.1016/j.pbb.2008.10.007
10.1097/JCP.0000000000001324
10.3390/antiox12091725
10.3389/fphar.2020.01021
10.3390/genes13040646
10.2174/1570159X11311040002
10.1016/j.jad.2014.06.001
10.12659/MSM.896217
10.3233/JAD-2006-10101
10.1186/1476-4598-10-12
10.3390/molecules23112778
10.3390/molecules24152839
10.1016/j.bbih.2022.100518
10.1016/j.arcmed.2007.07.011
10.3389/fmicb.2019.00912
10.3390/ijms22010196
10.1016/j.jad.2010.04.012
10.3390/nano11010002
10.3988/jcn.2021.17.4.503
10.3389/fnins.2023.1153439
10.1111/eip.12775
10.1080/10408398.2019.1653260
10.3390/foods6100092
10.31887/DCNS.2018.20.3/pschulz
10.1002/ptr.5524
10.1021/jf100135h
10.1016/B978-0-443-13587-3.00004-7
10.1016/j.jtcme.2016.08.002
10.1139/apnm-2013-0133
10.1017/S1461145708009310
10.1016/j.ejphar.2016.05.026
10.1038/s41398-019-0570-y
10.2174/138945011794815356
10.1016/j.bbadis.2014.12.005
10.3922/j.psns.2010.2.013
10.1002/j.2051-5545.2010.tb00298.x
10.1007/s11011-018-0352-x
10.3390/biom9020056
10.3390/ijms21062194
10.1016/j.brainres.2016.03.010
10.1021/acs.jafc.5b00244
10.2174/1874467215666220509213122
10.1006/phrs.1998.0404
10.1016/j.nrl.2019.06.002
10.1002/ptr.6125
10.1007/s00709-015-0821-6
10.2217/epi-2016-0106
10.2147/DDDT.S327378
10.3390/ijms24032258
10.3389/fphar.2018.00386
10.3390/ma14123332
10.1111/bph.13621
10.1016/j.nbd.2020.105136
10.1186/s13008-015-0012-z
10.1097/JCP.0000000000001012
10.3233/JAD-170512
10.1016/j.schres.2017.09.046
10.1016/j.jamda.2016.12.071
10.1007/s12640-017-9860-4
10.1021/acsomega.2c07326
10.1515/aoas-2015-0079
10.1002/biof.1533
10.1124/jpet.116.237503
10.3839/jabc.2018.027
10.3390/ijms17050733
10.1007/s11655-015-2160-z
10.3389/fpsyt.2020.572533
10.1016/j.intimp.2010.11.013
10.1002/biof.1932
10.3389/fncel.2018.00516
10.1586/14737175.2015.1044981
10.1002/ptr.5211
10.1016/j.autrev.2017.11.016
10.1016/j.jad.2024.01.023
10.1016/j.neulet.2009.01.028
10.1016/j.pnpbp.2009.01.006
10.1097/WNF.0000000000000344
10.1016/j.biopha.2018.09.106
10.1001/jamapsychiatry.2022.2066
10.1007/978-981-32-9721-0_24
10.3390/biom10091323
10.1080/1028415X.2024.2325233
10.1016/j.jpba.2018.04.034
10.1016/j.domaniend.2010.06.004
10.1016/j.neuropharm.2018.04.003
10.1016/j.ejphar.2013.12.028
10.1016/j.bcp.2007.08.016
10.1100/tsw.2009.137
10.1016/j.neuropharm.2009.06.010
10.1002/jcp.28103
10.1016/j.biopsych.2011.04.013
10.1080/10837450.2019.1686524
10.1016/j.jep.2017.07.022
10.1016/j.csbj.2022.09.014
10.3389/fpsyt.2023.1068277
10.1016/j.jad.2008.04.013
10.1166/jnn.2016.12363
10.1177/0269881116686883
10.3390/ijms20102419
10.1002/da.22084
10.3390/molecules27010167
10.2174/1570159X11666131120230309
10.1016/j.eurpsy.2007.01.100
10.1002/biof.1302
10.3390/antiox7040046
10.1038/mp.2016.3
10.1007/978-0-387-46401-5_8
10.1016/j.cellsig.2015.06.003
10.1007/s00213-008-1300-y
10.1016/j.intimp.2016.05.007
10.4161/oxim.2.2.7944
10.4049/jimmunol.174.12.8116
10.1016/j.jmgm.2017.10.022
10.1016/j.jad.2016.09.047
10.1155/2014/828702
10.3390/ijms20051033
10.1021/acs.jafc.0c07578
10.1016/j.pneurobio.2016.07.004
10.1089/ars.2005.7.32
10.3390/ph13070153
10.1002/wps.20693
10.1016/j.pnpbp.2012.08.017
10.1016/j.nutres.2019.05.001
10.1021/acs.jnatprod.7b00425
10.1016/j.jpsychires.2011.03.002
10.1002/ptr.6571
10.31887/DCNS.2017.19.2/bbandelow
10.1016/j.pnpbp.2009.10.016
10.1615/CritRevTherDrugCarrierSyst.2013007236
10.1111/nyas.13712
10.3390/molecules28020742
10.1016/j.psyneuen.2018.02.031
10.1007/s12010-018-2866-4
10.1016/j.cyto.2021.155541
10.1186/s12974-015-0332-6
ContentType Journal Article
Copyright 2024 John Wiley & Sons Ltd.
2024 John Wiley & Sons, Ltd.
Copyright_xml – notice: 2024 John Wiley & Sons Ltd.
– notice: 2024 John Wiley & Sons, Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7QP
7QR
7TK
7TM
8FD
FR3
K9.
P64
RC3
7X8
7S9
L.6
DOI 10.1002/ptr.8265
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Biotechnology Research Abstracts
Technology Research Database
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList MEDLINE - Academic
AGRICOLA
MEDLINE
Genetics Abstracts

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
Botany
EISSN 1099-1573
EndPage 4260
ExternalDocumentID 38965868
10_1002_ptr_8265
PTR8265
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
123
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHBH
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAYOK
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
EBD
EBS
ECGQY
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
GWYGA
H.X
HF~
HGLYW
HHY
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6Q
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
V2E
V8K
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WOHZO
WQJ
WRC
WUP
WVDHM
WWP
WXI
WXSBR
XG1
XV2
YCJ
ZZTAW
~IA
~KM
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
AIQQE
CITATION
O8X
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7QP
7QR
7TK
7TM
8FD
FR3
K9.
P64
RC3
7X8
7S9
L.6
ID FETCH-LOGICAL-c3825-218ca943a37f82f9ed1d6d26dbe372b4a0f8fb75422667588e3c40596b1bec0a3
IEDL.DBID DRFUL
ISICitedReferencesCount 7
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001262151500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0951-418X
1099-1573
IngestDate Fri Sep 05 17:23:16 EDT 2025
Thu Sep 04 18:00:08 EDT 2025
Sat Nov 29 14:43:15 EST 2025
Wed Feb 19 02:05:34 EST 2025
Tue Nov 18 21:56:40 EST 2025
Sat Nov 29 03:30:46 EST 2025
Wed Jan 22 17:17:07 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords nanocurcumin
curcumin
psychiatric disorders
Language English
License 2024 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3825-218ca943a37f82f9ed1d6d26dbe372b4a0f8fb75422667588e3c40596b1bec0a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-5001-2953
0000-0002-4883-6902
PMID 38965868
PQID 3092294872
PQPubID 1036338
PageCount 21
ParticipantIDs proquest_miscellaneous_3153729081
proquest_miscellaneous_3076019796
proquest_journals_3092294872
pubmed_primary_38965868
crossref_primary_10_1002_ptr_8265
crossref_citationtrail_10_1002_ptr_8265
wiley_primary_10_1002_ptr_8265_PTR8265
PublicationCentury 2000
PublicationDate August 2024
2024-08-00
2024-Aug
20240801
PublicationDateYYYYMMDD 2024-08-01
PublicationDate_xml – month: 08
  year: 2024
  text: August 2024
PublicationDecade 2020
PublicationPlace Chichester, UK
PublicationPlace_xml – name: Chichester, UK
– name: England
– name: Bognor Regis
PublicationSubtitle PTR
PublicationTitle Phytotherapy research
PublicationTitleAlternate Phytother Res
PublicationYear 2024
Publisher John Wiley & Sons, Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Ltd
– name: Wiley Subscription Services, Inc
References 2021; 69
2017; 80
2010; 15
2006; 31
2005; 174
2010; 19
2019; 10
2024; 349
2019; 13
2019; 12
2008; 39
2016; 784
2016; 30
2022; 26
2020; 13
2017; 152
2022; 20
2020; 11
2024
2020; 10
2016; 36
2022; 27
2020; 19
2009; 12
2017; 207
2018; 7
2017; 209
2018; 9
2018; 3
2009; 92
2019; 20
2024; 8
2019; 24
2011; 70
2013; 239
2016; 42
2022; 37
2010; 3
2008; 111
2018; 33
2018; 32
2014; 12
2010; 9
2010; 34
2019; 9
2010; 37
2011; 1
2018; 108
2010; 39
2019; 34
2019; 39
2009; 452
2015; 1852
2020; 34
2014; 2014
2020; 146
2021; 143
2018; 23
2016; 17
2016; 16
2018; 20
2019; 187
2016; 6
2018; 17
2023; 46
2018; 195
2009; 70
2019; 42
2023; 49
1999; 39
2019; 45
2015; 63
2016; 21
2022; 13
2019; 49
2018; 91
2005; 7
2020; 25
2020; 22
2014; 39
2020; 21
2022; 11
2018; 12
2018; 16
2016; 22
2017; 6
2017; 7
2021; 27
2010; 58
2020; 60
2023; 8
2011; 11
2011; 10
2016; 1642
2011; 12
2008; 75
2017; 9
2014; 724
2020; 6
2017; 31
2009; 57
2023; 24
2023; 28
2013; 11
2023; 26
2018; 135
2020; 9
2019; 69
2022; 79
2019; 234
2017; 360
2021; 41
2007; 22
2014; 167
2018; 79
2015; 12
2015; 15
2023; 12
2012
2023; 17
2006; 10
2023; 16
2013; 40
2010; 126
2015; 10
2017; 174
2018; 61
2008; 201
2021; 14
2009; 33
2019; 1437
2021; 15
2015; 27
2015; 29
2023
2017; 16
2007; 595
2021; 17
2018; 156
2015; 21
2013; 30
2019
2009; 9
2016; 253
2017; 19
2011; 45
2017; 18
2009; 2
e_1_2_14_114_1
e_1_2_14_137_1
e_1_2_14_73_1
e_1_2_14_96_1
e_1_2_14_110_1
e_1_2_14_31_1
e_1_2_14_50_1
e_1_2_14_92_1
e_1_2_14_35_1
e_1_2_14_12_1
Nakhlband A. (e_1_2_14_107_1) 2011; 1
e_1_2_14_77_1
Sun X. (e_1_2_14_138_1) 2006; 31
e_1_2_14_16_1
e_1_2_14_58_1
e_1_2_14_6_1
e_1_2_14_140_1
El‐Shamarka M. E. (e_1_2_14_39_1) 2023; 26
e_1_2_14_121_1
e_1_2_14_163_1
e_1_2_14_125_1
e_1_2_14_103_1
e_1_2_14_148_1
e_1_2_14_85_1
e_1_2_14_129_1
e_1_2_14_2_1
e_1_2_14_20_1
e_1_2_14_62_1
e_1_2_14_81_1
e_1_2_14_24_1
e_1_2_14_43_1
e_1_2_14_66_1
e_1_2_14_28_1
e_1_2_14_89_1
e_1_2_14_47_1
Jakubczyk K. (e_1_2_14_68_1) 2020; 9
e_1_2_14_151_1
Belcaro G. (e_1_2_14_18_1) 2010; 15
e_1_2_14_119_1
e_1_2_14_132_1
e_1_2_14_155_1
e_1_2_14_115_1
e_1_2_14_136_1
e_1_2_14_72_1
e_1_2_14_95_1
e_1_2_14_159_1
e_1_2_14_111_1
e_1_2_14_30_1
e_1_2_14_53_1
e_1_2_14_91_1
e_1_2_14_11_1
e_1_2_14_34_1
e_1_2_14_57_1
e_1_2_14_15_1
e_1_2_14_38_1
e_1_2_14_76_1
e_1_2_14_99_1
e_1_2_14_120_1
e_1_2_14_143_1
e_1_2_14_162_1
e_1_2_14_7_1
e_1_2_14_108_1
e_1_2_14_124_1
e_1_2_14_147_1
e_1_2_14_104_1
e_1_2_14_84_1
Ghoushi E. (e_1_2_14_51_1) 2024; 8
e_1_2_14_128_1
e_1_2_14_100_1
e_1_2_14_80_1
e_1_2_14_61_1
e_1_2_14_23_1
e_1_2_14_46_1
e_1_2_14_65_1
e_1_2_14_27_1
e_1_2_14_88_1
e_1_2_14_69_1
e_1_2_14_150_1
Rahimi H. R. (e_1_2_14_123_1) 2016; 6
e_1_2_14_131_1
e_1_2_14_154_1
e_1_2_14_116_1
e_1_2_14_135_1
e_1_2_14_158_1
e_1_2_14_94_1
e_1_2_14_112_1
e_1_2_14_139_1
e_1_2_14_75_1
e_1_2_14_52_1
e_1_2_14_90_1
e_1_2_14_71_1
e_1_2_14_10_1
e_1_2_14_56_1
e_1_2_14_33_1
e_1_2_14_14_1
Fakhraei N. (e_1_2_14_42_1) 2018; 3
e_1_2_14_98_1
e_1_2_14_79_1
Zhang Z.‐B. (e_1_2_14_161_1) 2018; 9
e_1_2_14_165_1
e_1_2_14_8_1
e_1_2_14_142_1
e_1_2_14_105_1
e_1_2_14_146_1
e_1_2_14_60_1
e_1_2_14_83_1
e_1_2_14_127_1
e_1_2_14_101_1
e_1_2_14_41_1
e_1_2_14_64_1
e_1_2_14_4_1
e_1_2_14_45_1
e_1_2_14_22_1
e_1_2_14_87_1
e_1_2_14_49_1
e_1_2_14_26_1
Goldstein B. I. (e_1_2_14_54_1) 2009; 70
e_1_2_14_19_1
Nakhlband A. (e_1_2_14_109_1) 2011; 1
e_1_2_14_130_1
e_1_2_14_153_1
e_1_2_14_117_1
e_1_2_14_134_1
Dunlavey C. J. (e_1_2_14_37_1) 2018; 16
e_1_2_14_157_1
e_1_2_14_113_1
e_1_2_14_74_1
e_1_2_14_97_1
e_1_2_14_70_1
e_1_2_14_93_1
e_1_2_14_13_1
e_1_2_14_32_1
e_1_2_14_55_1
Urošević M. (e_1_2_14_144_1) 2022; 11
e_1_2_14_17_1
e_1_2_14_36_1
e_1_2_14_59_1
e_1_2_14_78_1
e_1_2_14_29_1
e_1_2_14_160_1
e_1_2_14_141_1
e_1_2_14_164_1
e_1_2_14_5_1
e_1_2_14_122_1
e_1_2_14_145_1
e_1_2_14_9_1
e_1_2_14_106_1
e_1_2_14_126_1
e_1_2_14_149_1
e_1_2_14_102_1
e_1_2_14_86_1
e_1_2_14_63_1
e_1_2_14_40_1
e_1_2_14_82_1
e_1_2_14_67_1
e_1_2_14_21_1
e_1_2_14_44_1
e_1_2_14_25_1
e_1_2_14_48_1
Acton Q. A. (e_1_2_14_3_1) 2012
e_1_2_14_152_1
e_1_2_14_118_1
e_1_2_14_133_1
e_1_2_14_156_1
References_xml – volume: 8
  start-page: 10713
  issue: 12
  year: 2023
  end-page: 10746
  article-title: Curcumin formulations for better bioavailability: What we learned from clinical trials thus far?
  publication-title: ACS Omega
– volume: 209
  start-page: 1
  year: 2017
  end-page: 12
  article-title: Pharmacokinetic interactions of curcuminoids with conventional drugs: A review
  publication-title: Journal of Ethnopharmacology
– volume: 32
  start-page: 514
  issue: 3
  year: 2018
  end-page: 521
  article-title: Curcumin nanomicelle improves semen parameters, oxidative stress, inflammatory biomarkers, and reproductive hormones in infertile men: A randomized clinical trial
  publication-title: Phytotherapy Research
– volume: 234
  start-page: 12471
  issue: 8
  year: 2019
  end-page: 12482
  article-title: Impact of curcumin on toll‐like receptors
  publication-title: Journal of Cellular Physiology
– volume: 37
  start-page: 682
  issue: 8
  year: 2022
  end-page: 690
  article-title: Oxidative stress, the immune response, synaptic plasticity, and cognition in transgenic models of Alzheimer disease
  publication-title: Neurología
– volume: 6
  issue: 8
  year: 2020
  article-title: Self‐microemulsifying drug delivery system (SMEDDS) of curcumin attenuates depression in olfactory bulbectomized rats
  publication-title: Heliyon
– volume: 27
  start-page: 58
  issue: 1
  year: 2022
  end-page: 72
  article-title: Treatment resistance in psychiatry: State of the art and new directions
  publication-title: Molecular Psychiatry
– volume: 108
  start-page: 1244
  year: 2018
  end-page: 1252
  article-title: Curcumin loading potentiates the neuroprotective efficacy of Fe O magnetic nanoparticles in cerebellum cells of schizophrenic rats
  publication-title: Biomedicine & Pharmacotherapy
– volume: 6
  start-page: 383
  issue: 4
  year: 2016
  end-page: 398
  article-title: Novel delivery system for natural products: Nano‐curcumin formulations
  publication-title: Avicenna Journal of Phytomedicine
– volume: 16
  start-page: 9432
  issue: 9
  year: 2016
  end-page: 9442
  article-title: Design of curcumin loaded polymeric nanoparticles‐optimization, formulation and characterization
  publication-title: Journal of Nanoscience and Nanotechnology
– volume: 23
  start-page: 2778
  issue: 11
  year: 2018
  article-title: Immunomodulators inspired by nature: A review on curcumin and Echinacea
  publication-title: Molecules
– volume: 33
  start-page: 621
  issue: 3
  year: 2018
  end-page: 633
  article-title: Add‐on treatment with curcumin has antidepressive effects in Thai patients with major depression: Results of a randomized double‐blind placebo‐controlled study
  publication-title: Neurotoxicity Research
– volume: 12
  start-page: 447
  issue: 4
  year: 2009
  end-page: 458
  article-title: Brain‐derived neurotrophic factor and inflammatory markers in patients with early‐vs. late‐stage bipolar disorder
  publication-title: International Journal of Neuropsychopharmacology
– volume: 11
  issue: 2
  year: 2022
  article-title: Curcumin: Biological activities and modern pharmaceutical forms
  publication-title: Antibiotics (Basel).
– volume: 31
  start-page: 189
  issue: 3
  year: 2006
  end-page: 196
  article-title: Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder
  publication-title: Journal of Psychiatry and Neuroscience
– volume: 75
  start-page: 787
  issue: 4
  year: 2008
  end-page: 809
  article-title: Curcumin as "Curecumin": From kitchen to clinic
  publication-title: Biochemical Pharmacology
– volume: 63
  start-page: 7606
  issue: 35
  year: 2015
  end-page: 7614
  article-title: Degradation of curcumin: From mechanism to biological implications
  publication-title: Journal of Agricultural and Food Chemistry
– volume: 126
  start-page: 366
  issue: 3
  year: 2010
  end-page: 387
  article-title: Bipolar disorder and metabolic syndrome: An international perspective
  publication-title: Journal of Affective Disorders
– volume: 452
  start-page: 111
  issue: 2
  year: 2009
  end-page: 113
  article-title: Brain‐derived neurotrophic factor serum levels before and after treatment for acute mania
  publication-title: Neuroscience Letters
– volume: 70
  start-page: 663
  issue: 7
  year: 2011
  end-page: 671
  article-title: Meta‐analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects
  publication-title: Biological Psychiatry
– volume: 15
  start-page: 337
  issue: 4
  year: 2010
  end-page: 344
  article-title: Efficacy and safety of Meriva®, a curcumin‐phosphatidylcholine complex, during extended administration in osteoarthritis patients
  publication-title: Alternative Medicine Review
– volume: 3
  start-page: 58
  issue: 2
  year: 2018
  end-page: 64
  article-title: Nanocurcumine ameliorates lipopolysaccharide‐induced depressive‐like behavior in mice
  publication-title: Nanomedicine Research Journal
– volume: 28
  issue: 2
  year: 2023
  article-title: The effects of curcumin on inflammasome: Latest update
  publication-title: Molecules
– volume: 20
  issue: 10
  year: 2019
  article-title: Curcumin and heme oxygenase: Neuroprotection and beyond
  publication-title: International Journal of Molecular Sciences
– volume: 9
  start-page: 155
  issue: 3
  year: 2010
  end-page: 161
  article-title: Pathophysiology of depression: Do we have any solid evidence of interest to clinicians?
  publication-title: World Psychiatry
– volume: 7
  start-page: 32
  year: 2005
  end-page: 41
  article-title: Curcumin induces glutathione biosynthesis and inhibits NF‐κB activation and interleukin‐8 release in alveolar epithelial cells: Mechanism of free radical scavenging activity
  publication-title: Antioxidants & Redox Signaling
– volume: 595
  start-page: 197
  year: 2007
  end-page: 212
  article-title: Neuroprotective effects of curcumin
  publication-title: Advances in Experimental Medicine and Biology
– volume: 91
  start-page: 226
  year: 2018
  end-page: 234
  article-title: Prevalence and correlates of low‐grade systemic inflammation in adult psychiatric inpatients: An electronic health record‐based study
  publication-title: Psychoneuroendocrinology
– volume: 174
  start-page: 8116
  issue: 12
  year: 2005
  end-page: 8124
  article-title: Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF‐κB as potential targets
  publication-title: Journal of Immunology
– volume: 42
  start-page: 561
  issue: 6
  year: 2016
  end-page: 580
  article-title: Curcumin and insulin resistance‐molecular targets and clinical evidences
  publication-title: BioFactors
– start-page: 135
  year: 2023
  end-page: 160
– volume: 20
  start-page: 5054
  year: 2022
  end-page: 5064
  article-title: Classification for psychiatric disorders including schizophrenia, bipolar disorder, and major depressive disorder using machine learning
  publication-title: Computational and Structural Biotechnology Journal
– volume: 20
  issue: 5
  year: 2019
  article-title: A review of curcumin and its derivatives as anticancer agents
  publication-title: International Journal of Molecular Sciences
– volume: 39
  start-page: 182
  issue: 2
  year: 2019
  end-page: 184
  article-title: Effects of curcumin on cognitive functioning and inflammatory state in schizophrenia: A double‐blind, placebo‐controlled pilot trial
  publication-title: Journal of Clinical Psychopharmacology
– start-page: 491
  year: 2019
  end-page: 501
– volume: 21
  start-page: 2194
  issue: 6
  year: 2020
  article-title: Role of interleukin‐6 in depressive disorder
  publication-title: International Journal of Molecular Sciences
– volume: 111
  start-page: 135
  issue: 2–3
  year: 2008
  end-page: 144
  article-title: Oxidative stress markers in bipolar disorder: A meta‐analysis
  publication-title: Journal of Affective Disorders
– volume: 207
  start-page: 188
  year: 2017
  end-page: 196
  article-title: Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double‐blind, placebo‐controlled study
  publication-title: Journal of Affective Disorders
– volume: 69
  start-page: 3340
  issue: 11
  year: 2021
  end-page: 3350
  article-title: In vitro gastrointestinal stability of lipophilic polyphenols is dependent on their oil–water partitioning in emulsions: Studies on curcumin, resveratrol, and quercetin
  publication-title: Journal of Agricultural and Food Chemistry
– volume: 33
  start-page: 435
  issue: 3
  year: 2009
  end-page: 449
  article-title: Antidepressant‐like effects of curcumin on serotonergic receptor‐coupled AC‐cAMP pathway in chronic unpredictable mild stress of rats
  publication-title: Progress in Neuro‐Psychopharmacology and Biological Psychiatry
– volume: 60
  start-page: 2643
  issue: 15
  year: 2020
  end-page: 2653
  article-title: Curcumin for depression: A meta‐analysis
  publication-title: Critical Reviews in Food Science and Nutrition
– volume: 19
  start-page: 93
  issue: 2
  year: 2017
  end-page: 107
  article-title: Treatment of anxiety disorders
  publication-title: Dialogues in Clinical Neuroscience
– volume: 26
  year: 2022
  article-title: Anti‐inflammatory medications for the treatment of mental disorders: A scoping review
  publication-title: Brain, Behavior, & Immunity‐Health
– volume: 349
  start-page: 332
  year: 2024
  end-page: 341
  article-title: Dysfunction of neurotransmitter metabolism is associated with the severity of depression in first‐diagnosed, drug‐naïve depressed patients
  publication-title: Journal of Affective Disorders
– volume: 146
  year: 2020
  article-title: Molecular mechanisms of psychiatric diseases
  publication-title: Neurobiology of Disease
– volume: 16
  start-page: R59
  issue: 2
  year: 2018
  end-page: r60
  article-title: Introduction to the hypothalamic‐pituitary‐adrenal axis: Healthy and dysregulated stress responses, developmental stress and neurodegeneration
  publication-title: Journal of Undergraduate Neuroscience Education
– volume: 12
  start-page: 140
  issue: 2
  year: 2014
  end-page: 147
  article-title: Oxidative stress and psychological disorders
  publication-title: Current Neuropharmacology
– volume: 12
  start-page: 332
  issue: 3
  year: 2011
  end-page: 347
  article-title: The targets of curcumin
  publication-title: Current Drug Targets
– volume: 24
  start-page: 118
  issue: 2
  year: 2023
  end-page: 130
  article-title: Bidirectional relations between anxiety, depression, and cancer: A review
  publication-title: Current Drug Targets
– volume: 253
  start-page: 417
  issue: 2
  year: 2016
  end-page: 430
  article-title: Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin
  publication-title: Protoplasma
– volume: 39
  start-page: 41
  issue: 1
  year: 1999
  end-page: 47
  article-title: Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages
  publication-title: Pharmacological Research
– volume: 70
  start-page: 9049
  issue: 8
  year: 2009
  article-title: Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature
  publication-title: Journal of Clinical Psychiatry
– volume: 30
  start-page: 175
  issue: 2
  year: 2016
  end-page: 183
  article-title: The role of curcumin administration in patients with major depressive disorder: Mini meta‐analysis of clinical trials
  publication-title: Phytotherapy Research
– volume: 9
  start-page: 233
  issue: 1
  year: 2019
  article-title: Inflammation‐related biomarkers in major psychiatric disorders: A cross‐disorder assessment of reproducibility and specificity in 43 meta‐analyses
  publication-title: Translational Psychiatry
– start-page: 1
  year: 2024
  end-page: 15
  article-title: Natural compounds for oxidative stress and neuroprotection in schizophrenia: Composition, mechanisms, and therapeutic potential
  publication-title: Nutritional Neuroscience
– volume: 7
  start-page: 46
  issue: 4
  year: 2018
  article-title: Polymeric nanoparticles for increasing oral bioavailability of curcumin
  publication-title: Antioxidants
– volume: 9
  year: 2018
  article-title: Anti‐inflammatory effects of curcumin in microglial cells
  publication-title: Frontiers in Pharmacology
– volume: 12
  year: 2019
  article-title: Neuroprotective effects of curcumin on IL‐1β‐induced neuronal apoptosis and depression‐like behaviors caused by chronic stress in rats
  publication-title: Frontiers in Cellular Neuroscience
– volume: 12
  start-page: 114
  issue: 1
  year: 2015
  article-title: Systemic inflammation and microglial activation: Systematic review of animal experiments
  publication-title: Journal of Neuroinflammation
– volume: 167
  start-page: 368
  year: 2014
  end-page: 375
  article-title: Curcumin for the treatment of major depression: A randomised, double‐blind, placebo controlled study
  publication-title: Journal of Affective Disorders
– volume: 135
  start-page: 506
  year: 2018
  end-page: 513
  article-title: Antidepressant‐like effects of a novel curcumin derivative J147: Involvement of 5‐HT1A receptor
  publication-title: Neuropharmacology
– volume: 92
  start-page: 39
  issue: 1
  year: 2009
  end-page: 43
  article-title: Anti‐depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress‐induced behavioral, biochemical and neurochemical changes
  publication-title: Pharmacology, Biochemistry, and Behavior
– volume: 3
  start-page: 239
  issue: 2
  year: 2010
  end-page: 244
  article-title: Effects of curcumin on pentylenetetrazole‐induced anxiety‐like behaviors and associated changes in cognition and monoamine levels
  publication-title: Psychology & Neuroscience
– volume: 9
  issue: 11
  year: 2020
  article-title: Antioxidant potential of curcumin—A meta‐analysis of randomized clinical trials
  publication-title: Antioxidants (Basel).
– volume: 61
  start-page: 187
  year: 2018
  end-page: 190
  article-title: Inhibition of monoamine oxidase A and B by demethoxycurcumin and bisdemethoxycurcumin
  publication-title: Journal of Applied Biological Chemistry
– volume: 40
  start-page: 12
  year: 2013
  end-page: 17
  article-title: NMDA GluN2B receptors involved in the antidepressant effects of curcumin in the forced swim test
  publication-title: Progress in Neuro‐Psychopharmacology & Biological Psychiatry
– volume: 19
  start-page: 63
  issue: 2–3
  year: 2010
  end-page: 70
  article-title: Impacts of anti‐EGFR monoclonal antibody in prostate cancer PC3 cells
  publication-title: Human Antibodies
– volume: 360
  start-page: 201
  issue: 1
  year: 2017
  end-page: 205
  article-title: Oxidative stress and the central nervous system
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
– volume: 58
  start-page: 7376
  issue: 12
  year: 2010
  end-page: 7382
  article-title: Curcumin nanoparticles improve the physicochemical properties of curcumin and effectively enhance its antioxidant and antihepatoma activities
  publication-title: Journal of Agricultural and Food Chemistry
– volume: 80
  start-page: 2839
  issue: 10
  year: 2017
  end-page: 2844
  article-title: Oral ingestion and intraventricular injection of curcumin attenuates the effort‐related effects of the VMAT‐2 inhibitor tetrabenazine: Implications for motivational symptoms of depression
  publication-title: Journal of Natural Products
– volume: 45
  start-page: 995
  issue: 8
  year: 2011
  end-page: 1004
  article-title: Brain‐derived neurotrophic factor as a state‐marker of mood episodes in bipolar disorders: A systematic review and meta‐regression analysis
  publication-title: Journal of Psychiatric Research
– volume: 79
  start-page: 920
  issue: 9
  year: 2022
  end-page: 931
  article-title: Association of oxidative stress–induced nucleic acid damage with psychiatric disorders in adults: A systematic review and meta‐analysis
  publication-title: JAMA Psychiatry
– volume: 49
  start-page: 512
  year: 2023
  end-page: 533
  article-title: Effect of nano‐curcumin on various diseases: A comprehensive review of clinical trials
  publication-title: BioFactors
– volume: 15
  start-page: 629
  issue: 6
  year: 2015
  end-page: 637
  article-title: Clinical development of curcumin in neurodegenerative disease
  publication-title: Expert Review of Neurotherapeutics
– volume: 41
  start-page: 25
  issue: 1
  year: 2021
  end-page: 30
  article-title: Nanocurcumin as an add‐on to antipsychotic drugs for treatment of negative symptoms in patients with chronic schizophrenia: A randomized, double‐blind, placebo‐controlled study
  publication-title: Journal of Clinical Psychopharmacology
– volume: 29
  start-page: 17
  issue: 1
  year: 2015
  end-page: 21
  article-title: Investigation of the efficacy of adjunctive therapy with bioavailability‐boosted curcuminoids in major depressive disorder
  publication-title: Phytotherapy Research: PTR
– volume: 11
  start-page: 2
  issue: 1
  year: 2020
  article-title: Novel therapeutic delivery of nanocurcumin in central nervous system related disorders
  publication-title: Nanomaterials
– volume: 21
  start-page: 332
  issue: 5
  year: 2015
  end-page: 338
  article-title: An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial
  publication-title: Chinese Journal of Integrative Medicine
– volume: 156
  start-page: 189
  year: 2018
  end-page: 198
  article-title: An LC–MS/MS method for simultaneous determination of curcumin, curcumin glucuronide and curcumin sulfate in a phase II clinical trial
  publication-title: Journal of Pharmaceutical and Biomedical Analysis
– volume: 42
  start-page: 117
  issue: 4
  year: 2019
  end-page: 122
  article-title: Curcumin as add‐on to antipsychotic treatment in patients with chronic schizophrenia: A randomized, double‐blind, placebo‐controlled study
  publication-title: Clinical Neuropharmacology
– volume: 11
  year: 2020
  article-title: Curcumin in depression: Potential mechanisms of action and current evidence‐a narrative review
  publication-title: Frontiers in Psychiatry
– volume: 61
  start-page: 843
  issue: 3
  year: 2018
  end-page: 866
  article-title: Protective effects of Indian spice curcumin against amyloid‐β in Alzheimer's disease
  publication-title: Journal of Alzheimer's Disease
– start-page: 277
  year: 2024
  end-page: 292
– volume: 39
  start-page: 242
  issue: 2
  year: 2008
  end-page: 245
  article-title: Increased proapoptotic serum activity in patients with chronic mood disorders
  publication-title: Archives of Medical Research
– volume: 16
  start-page: 307
  issue: 3
  year: 2023
  end-page: 320
  article-title: Berberine: Is it a promising agent for mental disorders treatment?
  publication-title: Current Molecular Pharmacology
– volume: 1642
  start-page: 219
  year: 2016
  end-page: 225
  article-title: Analysis of anti‐depressant potential of curcumin against depression induced male albino wistar rats
  publication-title: Brain Research
– volume: 46
  start-page: 835
  issue: 3
  year: 2023
  end-page: 852
  article-title: Therapeutic potential of targeting the NLRP3 inflammasome in rheumatoid arthritis
  publication-title: Inflammation
– volume: 724
  start-page: 132
  year: 2014
  end-page: 139
  article-title: Neuroprotective and antioxidant effects of curcumin in a ketamine‐induced model of mania in rats
  publication-title: European Journal of Pharmacology.
– volume: 27
  start-page: 2131
  issue: 10
  year: 2015
  end-page: 2136
  article-title: Epigenetic signaling in schizophrenia
  publication-title: Cellular Signalling
– volume: 22
  start-page: 196
  issue: 1
  year: 2020
  article-title: Curcumin and its derivatives as theranostic agents in Alzheimer's disease: The implication of nanotechnology
  publication-title: International Journal of Molecular Sciences
– volume: 9
  start-page: 56
  issue: 2
  year: 2019
  article-title: Formulations of curcumin nanoparticles for brain diseases
  publication-title: Biomolecules
– volume: 1
  start-page: 7
  issue: 1
  year: 2011
  end-page: 22
  article-title: Impacts of nanomedicines in ocular pharmacotherapy
  publication-title: BioImpacts: BI
– volume: 12
  start-page: 1725
  issue: 9
  year: 2023
  article-title: Dual action of curcumin as an anti‐ and pro‐oxidant from a biophysical perspective
  publication-title: Antioxidants
– volume: 8
  year: 2024
  article-title: Curcumin as a regulator of Th17 cells: Unveiling the mechanisms
  publication-title: Food Chemistry
– volume: 239
  start-page: 27
  year: 2013
  end-page: 30
  article-title: Antidepressant‐like effects of curcumin in WKY rat model of depression is associated with an increase in hippocampal BDNF
  publication-title: Behavioural Brain Research
– volume: 10
  start-page: 1
  issue: 1
  year: 2006
  end-page: 7
  article-title: Curcuminoids enhance amyloid‐beta uptake by macrophages of Alzheimer's disease patients
  publication-title: Journal of Alzheimer's Disease
– volume: 13
  issue: 7
  year: 2020
  article-title: Curcumin, a natural antimicrobial agent with strain‐specific activity
  publication-title: Pharmaceuticals (Basel)
– volume: 6
  start-page: 92
  issue: 10
  year: 2017
  article-title: Curcumin: A review of its effects on human health
  publication-title: Food
– volume: 34
  start-page: 297
  issue: 1
  year: 2019
  end-page: 308
  article-title: Curcumin restores rotenone induced depressive‐like symptoms in animal model of neurotoxicity: Assessment by social interaction test and sucrose preference test
  publication-title: Metabolic Brain Disease
– volume: 1437
  start-page: 57
  issue: 1
  year: 2019
  end-page: 67
  article-title: Inflammation in psychiatric disorders: What comes first?
  publication-title: Annals of the New York Academy of Sciences
– volume: 25
  start-page: 316
  issue: 3
  year: 2020
  end-page: 325
  article-title: Anti‐depressant effect of curcumin‐loaded guanidine‐chitosan thermo‐sensitive hydrogel by nasal delivery
  publication-title: Pharmaceutical Development and Technology
– volume: 784
  start-page: 192
  year: 2016
  end-page: 198
  article-title: Curcumin in depressive disorders: An overview of potential mechanisms, preclinical and clinical findings
  publication-title: European Journal of Pharmacology
– volume: 174
  start-page: 1325
  issue: 11
  year: 2017
  end-page: 1348
  article-title: Curcumin, the golden nutraceutical: Multitargeting for multiple chronic diseases
  publication-title: British Journal of Pharmacology
– volume: 1
  start-page: 153
  issue: 3
  year: 2011
  end-page: 159
  article-title: Barrier functionality of porcine and bovine brain capillary endothelial cells
  publication-title: BioImpacts: BI
– volume: 22
  start-page: S25
  issue: S1
  year: 2007
  article-title: Depression and HPA‐axis dysregulation: A large cohort study
  publication-title: European Psychiatry
– volume: 152
  start-page: 3
  year: 2017
  end-page: 20
  article-title: New drug developments in psychosis: Challenges, opportunities and strategies
  publication-title: Progress in Neurobiology
– volume: 17
  start-page: 733
  issue: 5
  year: 2016
  article-title: Pathogenetic and therapeutic applications of tumor necrosis factor‐α (TNF‐α) in major depressive disorder: A systematic review
  publication-title: International Journal of Molecular Sciences
– volume: 18
  start-page: 503
  issue: 6
  year: 2017
  end-page: 508
  article-title: Clinical use of curcumin in depression: A meta‐analysis
  publication-title: Journal of the American Medical Directors Association
– volume: 79
  start-page: 1
  year: 2018
  end-page: 14
  article-title: Metal chelating ability and antioxidant properties of curcumin‐metal complexes – A DFT approach
  publication-title: Journal of Molecular Graphics and Modelling
– volume: 39
  start-page: 231
  issue: 4
  year: 2010
  end-page: 239
  article-title: Curcumin attenuates the effects of transport stress on serum cortisol concentration, hippocampal NO production, and BDNF expression in the pig
  publication-title: Domestic Animal Endocrinology
– volume: 31
  start-page: 287
  issue: 3
  year: 2017
  end-page: 302
  article-title: Curcumin for neuropsychiatric disorders: A review of in vitro, animal and human studies
  publication-title: Journal of Psychopharmacology
– volume: 27
  issue: 1
  year: 2021
  article-title: Nrf2 regulation by curcumin: Molecular aspects for therapeutic prospects
  publication-title: Molecules
– volume: 7
  start-page: 339
  issue: 3
  year: 2017
  end-page: 346
  article-title: Curcumin: An age‐old anti‐inflammatory and anti‐neoplastic agent
  publication-title: Journal of Traditional and Complementary Medicine
– volume: 2014
  start-page: 1
  year: 2014
  end-page: 5
  article-title: Lipid peroxidation in psychiatric illness: Overview of clinical evidence
  publication-title: Oxidative Medicine and Cellular Longevity
– volume: 2
  start-page: 63
  issue: 2
  year: 2009
  end-page: 67
  article-title: Oxidative stress and anxiety: Relationship and cellular pathways
  publication-title: Oxidative Medicine and Cellular Longevity
– volume: 9
  issue: 1181
  year: 2018
  article-title: Curcumin's metabolites, tetrahydrocurcumin and octahydrocurcumin, possess superior anti‐inflammatory effects in vivo through suppression of TAK1‐NF‐κB pathway
  publication-title: Frontiers in Pharmacology
– volume: 24
  issue: 15
  year: 2019
  article-title: Dietary curcumin prevented astrocytosis, microgliosis, and apoptosis caused by acute and chronic exposure to ozone
  publication-title: Molecules
– volume: 37
  start-page: 596
  issue: 3
  year: 2010
  end-page: 603
  article-title: Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients
  publication-title: Neurobiology of Disease
– volume: 11
  year: 2020
  article-title: Turmeric and its major compound curcumin on health: Bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications
  publication-title: Frontiers Pharmacology
– volume: 9
  start-page: 721
  issue: 5
  year: 2017
  end-page: 736
  article-title: Understanding epigenetics of schizophrenia in the backdrop of its antipsychotic drug therapy
  publication-title: Epigenomics
– volume: 24
  issue: 3
  year: 2023
  article-title: Anti‐inflammatory, antioxidant, and neuroprotective effects of polyphenols‐polyphenols as an element of diet therapy in depressive disorders
  publication-title: International Journal of Molecular Sciences
– volume: 57
  start-page: 463
  issue: 4
  year: 2009
  end-page: 471
  article-title: Curcumin reverses impaired cognition and neuronal plasticity induced by chronic stress
  publication-title: Neuropharmacology
– volume: 20
  start-page: 207
  issue: 3
  year: 2018
  end-page: 214
  article-title: Alternative and complementary approaches in psychiatry: Beliefs versus evidence
  publication-title: Dialogues in Clinical Neuroscience
– volume: 201
  start-page: 435
  issue: 3
  year: 2008
  end-page: 442
  article-title: Antidepressant activity of curcumin: Involvement of serotonin and dopamine system
  publication-title: Psychopharmacology
– volume: 17
  year: 2023
  article-title: Oxidative stress impairs cognitive function by affecting hippocampal fimbria volume in drug‐naïve, first‐episode schizophrenia
  publication-title: Frontiers in Neuroscience
– volume: 15
  start-page: 4503
  year: 2021
  end-page: 4525
  article-title: Anti‐inflammatory effects of curcumin in the inflammatory diseases: Status, limitations and countermeasures
  publication-title: Drug Design, Development and Therapy
– volume: 1852
  start-page: 951
  issue: 5
  year: 2015
  end-page: 961
  article-title: Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders
  publication-title: Biochimica et Biophysica Acta
– volume: 10
  start-page: 1
  issue: 1
  year: 2015
  end-page: 13
  article-title: Curcumin and tumor immune‐editing: Resurrecting the immune system
  publication-title: Cell Division
– volume: 143
  year: 2021
  article-title: Effect of curcumin on proinflammatory cytokines: A meta‐analysis of randomized controlled trials
  publication-title: Cytokine
– volume: 32
  start-page: 1865
  issue: 10
  year: 2018
  end-page: 1875
  article-title: Curcumin in epilepsy disorders
  publication-title: Phytotherapy Research
– year: 2023
  article-title: The effect of adding curcumin to sodium valproate in treatment of patients with bipolar disorder in the acute phase of mania: A clinical trial
  publication-title: Frontiers in Psychiatry
– volume: 45
  start-page: 666
  issue: 5
  year: 2019
  end-page: 689
  article-title: Benefits of curcumin in brain disorders
  publication-title: BioFactors
– volume: 13
  start-page: 1032
  issue: 5
  year: 2019
  end-page: 1049
  article-title: Putative neuroprotective pharmacotherapies to target the staged progression of mental illness
  publication-title: Early Intervention in Psychiatry
– volume: 187
  start-page: 1096
  issue: 3
  year: 2019
  end-page: 1112
  article-title: Electrocortical and biochemical evaluation of antidepressant efficacy of formulated nanocurcumin
  publication-title: Applied Biochemistry and Biotechnology
– volume: 30
  start-page: 331
  issue: 4
  year: 2013
  end-page: 368
  article-title: Nanocurcumin: A promising therapeutic advancement over native curcumin
  publication-title: Critical Reviews™ in Therapeutic Drug Carrier Systems
– volume: 39
  start-page: 211
  issue: 2
  year: 2014
  end-page: 218
  article-title: Effects of curcumin on brain‐derived neurotrophic factor levels and oxidative damage in obesity and diabetes
  publication-title: Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition et Metabolisme
– volume: 26
  start-page: 139
  issue: 2
  year: 2023
  end-page: 147
  article-title: Curcumin modulation of L‐dopa and rasagiline‐induced neuroprotection in rotenone model of Parkinson's disease
  publication-title: Iranian Journal of Basic Medical Sciences
– volume: 21
  start-page: 1696
  issue: 12
  year: 2016
  end-page: 1709
  article-title: A meta‐analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression
  publication-title: Molecular Psychiatry
– volume: 17
  start-page: 503
  issue: 4
  year: 2021
  end-page: 515
  article-title: How inflammation affects the brain in depression: A review of functional and structural MRI studies
  publication-title: Journal of Clinical Neurology
– year: 2012
– volume: 10
  start-page: 12
  year: 2011
  article-title: Curcumin: A review of anti‐cancer properties and therapeutic activity in head and neck squamous cell carcinoma
  publication-title: Molecular Cancer
– volume: 195
  start-page: 572
  year: 2018
  end-page: 573
  article-title: The effects of curcumin on brain‐derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study
  publication-title: Schizophrenia Research
– volume: 16
  start-page: 489
  issue: 2
  year: 2016
  end-page: 505
  article-title: Effect of dietary supplementation of garlic (Allium sativum) and turmeric (Curcuma longa) on growth performance, carcass traits, blood profile and oxidative status in growing rabbits
  publication-title: Annals of Animal Science
– volume: 36
  start-page: 282
  year: 2016
  end-page: 290
  article-title: PI3k/Akt signalling pathway plays a crucial role in the anti‐inflammatory effects of curcumin in LPS‐activated microglia
  publication-title: International Immunopharmacology
– volume: 49
  start-page: 1958
  issue: 12
  year: 2019
  end-page: 1970
  article-title: Prevalence of low‐grade inflammation in depression: A systematic review and meta‐analysis of CRP levels
  publication-title: Psychological Medicine
– volume: 34
  start-page: 147
  issue: 1
  year: 2010
  end-page: 153
  article-title: Curcumin produces neuroprotective effects via activating brain‐derived neurotrophic factor/TrkB‐dependent MAPK and PI‐3K cascades in rodent cortical neurons
  publication-title: Progress in Neuro‐Psychopharmacology and Biological Psychiatry
– volume: 9
  start-page: 1233
  year: 2009
  end-page: 1241
  article-title: Potentials of curcumin as an antidepressant
  publication-title: The Scientific World Journal
– volume: 17
  start-page: 125
  issue: 2
  year: 2018
  end-page: 135
  article-title: Curcumin: A natural modulator of immune cells in systemic lupus erythematosus
  publication-title: Autoimmunity Reviews
– volume: 10
  year: 2019
  article-title: Anti‐infective properties of the golden spice curcumin
  publication-title: Frontiers in Microbiology
– volume: 27
  start-page: 36
  issue: 1
  year: 2021
  end-page: 47
  article-title: Peripheral inflammation and blood‐brain barrier disruption: Effects and mechanisms
  publication-title: CNS Neuroscience & Therapeutics
– volume: 22
  start-page: 2035
  year: 2016
  end-page: 2042
  article-title: Curcumin ameliorates ischemia‐induced limb injury through immunomodulation
  publication-title: Medical Science Monitor
– start-page: 1021
  year: 2012
  end-page: 1036
– volume: 11
  start-page: 338
  issue: 4
  year: 2013
  end-page: 378
  article-title: Curcumin and its derivatives: Their application in neuropharmacology and neuroscience in the 21st century
  publication-title: Current Neuropharmacology
– year: 2023
– volume: 12
  start-page: 290
  issue: 2
  year: 2018
  end-page: 296
  article-title: Formulated curcumin nanoparticles mitigate brain oxidative stress induced by reserpine in rats
  publication-title: Journal of Bionanoscience
– volume: 34
  start-page: 896
  issue: 4
  year: 2020
  end-page: 903
  article-title: Beneficial effects of nano‐curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double‐blind, placebo‐controlled clinical trial
  publication-title: Phytotherapy Research
– volume: 19
  start-page: 15
  issue: 1
  year: 2020
  end-page: 33
  article-title: Dopamine and glutamate in schizophrenia: Biology, symptoms and treatment
  publication-title: World Psychiatry
– volume: 13
  issue: 4
  year: 2022
  article-title: Major depressive disorder: Existing hypotheses about pathophysiological mechanisms and new genetic findings
  publication-title: Genes (Basel)
– volume: 10
  issue: 9
  year: 2020
  article-title: Curcumin inhibits the primary nucleation of amyloid‐beta peptide: A molecular dynamics study
  publication-title: Biomolecules
– volume: 14
  start-page: 3332
  issue: 12
  year: 2021
  article-title: Action mechanisms of curcumin in Alzheimer's disease and its brain targeted delivery
  publication-title: Materials
– volume: 11
  start-page: 179
  issue: 2
  year: 2011
  end-page: 186
  article-title: Curcumin promotes degradation of inducible nitric oxide synthase and suppresses its enzyme activity in RAW 264.7 cells
  publication-title: International Immunopharmacology
– volume: 30
  start-page: 297
  issue: 4
  year: 2013
  end-page: 306
  article-title: Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits
  publication-title: Depression and Anxiety
– volume: 16
  start-page: 266
  issue: 3
  year: 2017
  end-page: 278
  article-title: How immune‐inflammatory processes link CNS and psychiatric disorders: Classification and treatment implications
  publication-title: CNS & Neurological Disorders‐Drug Targets
– volume: 69
  start-page: 1
  year: 2019
  end-page: 8
  article-title: Short‐term curcumin supplementation enhances serum brain‐derived neurotrophic factor in adult men and women: A systematic review and dose‐response meta‐analysis of randomized controlled trials
  publication-title: Nutrition Research (New York, NY).
– ident: e_1_2_14_113_1
  doi: 10.1007/978-981-19-7376-5_7
– ident: e_1_2_14_108_1
  doi: 10.2174/1389450123666220922094403
– ident: e_1_2_14_114_1
  doi: 10.1017/S0033291719001454
– ident: e_1_2_14_8_1
  doi: 10.1002/ptr.5998
– ident: e_1_2_14_66_1
  doi: 10.1016/j.bbr.2012.10.049
– volume: 6
  start-page: 383
  issue: 4
  year: 2016
  ident: e_1_2_14_123_1
  article-title: Novel delivery system for natural products: Nano‐curcumin formulations
  publication-title: Avicenna Journal of Phytomedicine
– ident: e_1_2_14_49_1
  doi: 10.1007/s10753-023-01795-5
– volume: 70
  start-page: 9049
  issue: 8
  year: 2009
  ident: e_1_2_14_54_1
  article-title: Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature
  publication-title: Journal of Clinical Psychiatry
– ident: e_1_2_14_126_1
  doi: 10.3233/HAB-2010-0229
– ident: e_1_2_14_65_1
  doi: 10.1111/cns.13569
– ident: e_1_2_14_96_1
  doi: 10.1016/B978-0-12-374947-5.00060-2
– ident: e_1_2_14_13_1
  doi: 10.1016/j.heliyon.2020.e04482
– ident: e_1_2_14_63_1
  doi: 10.1038/s41380-021-01200-3
– ident: e_1_2_14_10_1
  doi: 10.2174/1871527315666161122144659
– ident: e_1_2_14_105_1
  doi: 10.1166/jbns.2018.1524
– ident: e_1_2_14_81_1
  doi: 10.1016/j.nbd.2009.11.010
– ident: e_1_2_14_23_1
  doi: 10.1016/j.pbb.2008.10.007
– ident: e_1_2_14_62_1
  doi: 10.1097/JCP.0000000000001324
– ident: e_1_2_14_150_1
  doi: 10.3390/antiox12091725
– ident: e_1_2_14_135_1
  doi: 10.3389/fphar.2020.01021
– ident: e_1_2_14_74_1
  doi: 10.3390/genes13040646
– volume: 1
  start-page: 7
  issue: 1
  year: 2011
  ident: e_1_2_14_107_1
  article-title: Impacts of nanomedicines in ocular pharmacotherapy
  publication-title: BioImpacts: BI
– ident: e_1_2_14_87_1
  doi: 10.2174/1570159X11311040002
– ident: e_1_2_14_93_1
  doi: 10.1016/j.jad.2014.06.001
– ident: e_1_2_14_90_1
  doi: 10.12659/MSM.896217
– ident: e_1_2_14_159_1
  doi: 10.3233/JAD-2006-10101
– ident: e_1_2_14_148_1
  doi: 10.1186/1476-4598-10-12
– ident: e_1_2_14_29_1
  doi: 10.3390/molecules23112778
– ident: e_1_2_14_111_1
  doi: 10.3390/molecules24152839
– ident: e_1_2_14_45_1
  doi: 10.1016/j.bbih.2022.100518
– ident: e_1_2_14_119_1
  doi: 10.1016/j.arcmed.2007.07.011
– ident: e_1_2_14_120_1
  doi: 10.3389/fmicb.2019.00912
– ident: e_1_2_14_133_1
  doi: 10.3390/ijms22010196
– ident: e_1_2_14_99_1
  doi: 10.1016/j.jad.2010.04.012
– ident: e_1_2_14_117_1
  doi: 10.3390/nano11010002
– ident: e_1_2_14_56_1
  doi: 10.3988/jcn.2021.17.4.503
– ident: e_1_2_14_70_1
  doi: 10.3389/fnins.2023.1153439
– ident: e_1_2_14_127_1
  doi: 10.1111/eip.12775
– ident: e_1_2_14_48_1
  doi: 10.1080/10408398.2019.1653260
– ident: e_1_2_14_60_1
  doi: 10.3390/foods6100092
– ident: e_1_2_14_132_1
  doi: 10.31887/DCNS.2018.20.3/pschulz
– ident: e_1_2_14_9_1
  doi: 10.1002/ptr.5524
– ident: e_1_2_14_155_1
  doi: 10.1021/jf100135h
– ident: e_1_2_14_6_1
  doi: 10.1016/B978-0-443-13587-3.00004-7
– ident: e_1_2_14_41_1
  doi: 10.1016/j.jtcme.2016.08.002
– ident: e_1_2_14_47_1
  doi: 10.1139/apnm-2013-0133
– ident: e_1_2_14_76_1
  doi: 10.1017/S1461145708009310
– ident: e_1_2_14_77_1
  doi: 10.1016/j.ejphar.2016.05.026
– ident: e_1_2_14_158_1
  doi: 10.1038/s41398-019-0570-y
– ident: e_1_2_14_163_1
  doi: 10.2174/138945011794815356
– ident: e_1_2_14_151_1
  doi: 10.1016/j.bbadis.2014.12.005
– ident: e_1_2_14_31_1
  doi: 10.3922/j.psns.2010.2.013
– volume: 16
  start-page: R59
  issue: 2
  year: 2018
  ident: e_1_2_14_37_1
  article-title: Introduction to the hypothalamic‐pituitary‐adrenal axis: Healthy and dysregulated stress responses, developmental stress and neurodegeneration
  publication-title: Journal of Undergraduate Neuroscience Education
– ident: e_1_2_14_57_1
  doi: 10.1002/j.2051-5545.2010.tb00298.x
– ident: e_1_2_14_95_1
  doi: 10.1007/s11011-018-0352-x
– ident: e_1_2_14_121_1
  doi: 10.3390/biom9020056
– ident: e_1_2_14_140_1
  doi: 10.3390/ijms21062194
– ident: e_1_2_14_30_1
  doi: 10.1016/j.brainres.2016.03.010
– ident: e_1_2_14_131_1
  doi: 10.1021/acs.jafc.5b00244
– ident: e_1_2_14_136_1
  doi: 10.2174/1874467215666220509213122
– ident: e_1_2_14_2_1
  doi: 10.1006/phrs.1998.0404
– ident: e_1_2_14_19_1
  doi: 10.1016/j.nrl.2019.06.002
– ident: e_1_2_14_35_1
  doi: 10.1002/ptr.6125
– ident: e_1_2_14_146_1
  doi: 10.1007/s00709-015-0821-6
– ident: e_1_2_14_139_1
  doi: 10.2217/epi-2016-0106
– ident: e_1_2_14_118_1
  doi: 10.2147/DDDT.S327378
– ident: e_1_2_14_149_1
  doi: 10.3390/ijms24032258
– ident: e_1_2_14_157_1
  doi: 10.3389/fphar.2018.00386
– ident: e_1_2_14_38_1
  doi: 10.3390/ma14123332
– ident: e_1_2_14_86_1
  doi: 10.1111/bph.13621
– ident: e_1_2_14_25_1
  doi: 10.1016/j.nbd.2020.105136
– ident: e_1_2_14_27_1
  doi: 10.1186/s13008-015-0012-z
– ident: e_1_2_14_82_1
  doi: 10.1097/JCP.0000000000001012
– ident: e_1_2_14_125_1
  doi: 10.3233/JAD-170512
– ident: e_1_2_14_152_1
  doi: 10.1016/j.schres.2017.09.046
– ident: e_1_2_14_112_1
  doi: 10.1016/j.jamda.2016.12.071
– ident: e_1_2_14_75_1
  doi: 10.1007/s12640-017-9860-4
– ident: e_1_2_14_59_1
  doi: 10.1021/acsomega.2c07326
– ident: e_1_2_14_7_1
  doi: 10.1515/aoas-2015-0079
– ident: e_1_2_14_22_1
  doi: 10.1002/biof.1533
– ident: e_1_2_14_129_1
  doi: 10.1124/jpet.116.237503
– ident: e_1_2_14_14_1
  doi: 10.3839/jabc.2018.027
– volume: 15
  start-page: 337
  issue: 4
  year: 2010
  ident: e_1_2_14_18_1
  article-title: Efficacy and safety of Meriva®, a curcumin‐phosphatidylcholine complex, during extended administration in osteoarthritis patients
  publication-title: Alternative Medicine Review
– ident: e_1_2_14_94_1
  doi: 10.3390/ijms17050733
– ident: e_1_2_14_40_1
  doi: 10.1007/s11655-015-2160-z
– ident: e_1_2_14_124_1
  doi: 10.3389/fpsyt.2020.572533
– ident: e_1_2_14_20_1
  doi: 10.1016/j.intimp.2010.11.013
– ident: e_1_2_14_58_1
  doi: 10.1002/biof.1932
– ident: e_1_2_14_43_1
  doi: 10.3389/fncel.2018.00516
– ident: e_1_2_14_64_1
  doi: 10.1586/14737175.2015.1044981
– ident: e_1_2_14_116_1
  doi: 10.1002/ptr.5211
– volume: 11
  issue: 2
  year: 2022
  ident: e_1_2_14_144_1
  article-title: Curcumin: Biological activities and modern pharmaceutical forms
  publication-title: Antibiotics (Basel).
– ident: e_1_2_14_106_1
  doi: 10.1016/j.autrev.2017.11.016
– ident: e_1_2_14_162_1
  doi: 10.1016/j.jad.2024.01.023
– volume-title: Advances in physiology research and application: 2011
  year: 2012
  ident: e_1_2_14_3_1
– ident: e_1_2_14_142_1
  doi: 10.1016/j.neulet.2009.01.028
– ident: e_1_2_14_88_1
  doi: 10.1016/j.pnpbp.2009.01.006
– volume: 9
  issue: 11
  year: 2020
  ident: e_1_2_14_68_1
  article-title: Antioxidant potential of curcumin—A meta‐analysis of randomized clinical trials
  publication-title: Antioxidants (Basel).
– ident: e_1_2_14_103_1
  doi: 10.1097/WNF.0000000000000344
– ident: e_1_2_14_110_1
  doi: 10.1016/j.biopha.2018.09.106
– ident: e_1_2_14_72_1
  doi: 10.1001/jamapsychiatry.2022.2066
– ident: e_1_2_14_69_1
  doi: 10.1007/978-981-32-9721-0_24
– ident: e_1_2_14_36_1
  doi: 10.3390/biom10091323
– volume: 26
  start-page: 139
  issue: 2
  year: 2023
  ident: e_1_2_14_39_1
  article-title: Curcumin modulation of L‐dopa and rasagiline‐induced neuroprotection in rotenone model of Parkinson's disease
  publication-title: Iranian Journal of Basic Medical Sciences
– volume: 3
  start-page: 58
  issue: 2
  year: 2018
  ident: e_1_2_14_42_1
  article-title: Nanocurcumine ameliorates lipopolysaccharide‐induced depressive‐like behavior in mice
  publication-title: Nanomedicine Research Journal
– ident: e_1_2_14_79_1
  doi: 10.1080/1028415X.2024.2325233
– ident: e_1_2_14_85_1
  doi: 10.1016/j.jpba.2018.04.034
– ident: e_1_2_14_147_1
  doi: 10.1016/j.domaniend.2010.06.004
– volume: 1
  start-page: 153
  issue: 3
  year: 2011
  ident: e_1_2_14_109_1
  article-title: Barrier functionality of porcine and bovine brain capillary endothelial cells
  publication-title: BioImpacts: BI
– ident: e_1_2_14_89_1
  doi: 10.1016/j.neuropharm.2018.04.003
– ident: e_1_2_14_50_1
  doi: 10.1016/j.ejphar.2013.12.028
– ident: e_1_2_14_52_1
  doi: 10.1016/j.bcp.2007.08.016
– ident: e_1_2_14_83_1
  doi: 10.1100/tsw.2009.137
– volume: 8
  year: 2024
  ident: e_1_2_14_51_1
  article-title: Curcumin as a regulator of Th17 cells: Unveiling the mechanisms
  publication-title: Food Chemistry
– ident: e_1_2_14_153_1
  doi: 10.1016/j.neuropharm.2009.06.010
– ident: e_1_2_14_26_1
  doi: 10.1002/jcp.28103
– ident: e_1_2_14_102_1
  doi: 10.1016/j.biopsych.2011.04.013
– ident: e_1_2_14_122_1
  doi: 10.1080/10837450.2019.1686524
– ident: e_1_2_14_15_1
  doi: 10.1016/j.jep.2017.07.022
– ident: e_1_2_14_154_1
  doi: 10.1016/j.csbj.2022.09.014
– volume: 31
  start-page: 189
  issue: 3
  year: 2006
  ident: e_1_2_14_138_1
  article-title: Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder
  publication-title: Journal of Psychiatry and Neuroscience
– ident: e_1_2_14_5_1
  doi: 10.3389/fpsyt.2023.1068277
– ident: e_1_2_14_11_1
  doi: 10.1016/j.jad.2008.04.013
– ident: e_1_2_14_32_1
  doi: 10.1166/jnn.2016.12363
– ident: e_1_2_14_91_1
  doi: 10.1177/0269881116686883
– ident: e_1_2_14_100_1
  doi: 10.3390/ijms20102419
– ident: e_1_2_14_101_1
  doi: 10.1002/da.22084
– ident: e_1_2_14_134_1
  doi: 10.3390/molecules27010167
– ident: e_1_2_14_128_1
  doi: 10.2174/1570159X11666131120230309
– ident: e_1_2_14_165_1
  doi: 10.1016/j.eurpsy.2007.01.100
– ident: e_1_2_14_71_1
  doi: 10.1002/biof.1302
– ident: e_1_2_14_143_1
  doi: 10.3390/antiox7040046
– ident: e_1_2_14_53_1
  doi: 10.1038/mp.2016.3
– ident: e_1_2_14_34_1
  doi: 10.1007/978-0-387-46401-5_8
– ident: e_1_2_14_67_1
  doi: 10.1016/j.cellsig.2015.06.003
– ident: e_1_2_14_84_1
  doi: 10.1007/s00213-008-1300-y
– ident: e_1_2_14_33_1
  doi: 10.1016/j.intimp.2016.05.007
– ident: e_1_2_14_28_1
  doi: 10.4161/oxim.2.2.7944
– ident: e_1_2_14_80_1
  doi: 10.4049/jimmunol.174.12.8116
– ident: e_1_2_14_97_1
  doi: 10.1016/j.jmgm.2017.10.022
– ident: e_1_2_14_92_1
  doi: 10.1016/j.jad.2016.09.047
– ident: e_1_2_14_137_1
– ident: e_1_2_14_73_1
  doi: 10.1155/2014/828702
– ident: e_1_2_14_141_1
  doi: 10.3390/ijms20051033
– ident: e_1_2_14_164_1
  doi: 10.1021/acs.jafc.0c07578
– ident: e_1_2_14_78_1
  doi: 10.1016/j.pneurobio.2016.07.004
– ident: e_1_2_14_24_1
  doi: 10.1089/ars.2005.7.32
– ident: e_1_2_14_4_1
  doi: 10.3390/ph13070153
– ident: e_1_2_14_98_1
  doi: 10.1002/wps.20693
– volume: 9
  issue: 1181
  year: 2018
  ident: e_1_2_14_161_1
  article-title: Curcumin's metabolites, tetrahydrocurcumin and octahydrocurcumin, possess superior anti‐inflammatory effects in vivo through suppression of TAK1‐NF‐κB pathway
  publication-title: Frontiers in Pharmacology
– ident: e_1_2_14_160_1
  doi: 10.1016/j.pnpbp.2012.08.017
– ident: e_1_2_14_130_1
  doi: 10.1016/j.nutres.2019.05.001
– ident: e_1_2_14_156_1
  doi: 10.1021/acs.jnatprod.7b00425
– ident: e_1_2_14_44_1
  doi: 10.1016/j.jpsychires.2011.03.002
– ident: e_1_2_14_12_1
  doi: 10.1002/ptr.6571
– ident: e_1_2_14_16_1
  doi: 10.31887/DCNS.2017.19.2/bbandelow
– ident: e_1_2_14_145_1
  doi: 10.1016/j.pnpbp.2009.10.016
– ident: e_1_2_14_46_1
  doi: 10.1615/CritRevTherDrugCarrierSyst.2013007236
– ident: e_1_2_14_17_1
  doi: 10.1111/nyas.13712
– ident: e_1_2_14_21_1
  doi: 10.3390/molecules28020742
– ident: e_1_2_14_115_1
  doi: 10.1016/j.psyneuen.2018.02.031
– ident: e_1_2_14_104_1
  doi: 10.1007/s12010-018-2866-4
– ident: e_1_2_14_55_1
  doi: 10.1016/j.cyto.2021.155541
– ident: e_1_2_14_61_1
  doi: 10.1186/s12974-015-0332-6
SSID ssj0009204
Score 2.461196
SecondaryResourceType review_article
Snippet Psychiatric disorders cause long‐lasting disabilities across different age groups. While various medications are available for mental disorders, some patients...
Psychiatric disorders cause long-lasting disabilities across different age groups. While various medications are available for mental disorders, some patients...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 4240
SubjectTerms Animals
Antidepressants
Antidepressive Agents - pharmacology
Antidepressive Agents - therapeutic use
anxiety
Anxiety disorders
Anxiety Disorders - drug therapy
Bipolar disorder
Bipolar Disorder - drug therapy
Clinical trials
Curcumin
Curcumin - chemistry
Curcumin - pharmacology
Curcumin - therapeutic use
Depressive Disorder, Major - drug therapy
Dosage
Effectiveness
Humans
inflammation
Inflammatory response
Liposomes - chemistry
Mental depression
Mental disorders
Mental Disorders - drug therapy
nanocurcumin
Nanoparticles
Nanoparticles - chemistry
Neuroprotection
Pathogenesis
phytotherapy
psychiatric disorders
Schizophrenia
Schizophrenia - drug therapy
Treatment resistance
Title Curcumin and nano‐curcumin applications in psychiatric disorders
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fptr.8265
https://www.ncbi.nlm.nih.gov/pubmed/38965868
https://www.proquest.com/docview/3092294872
https://www.proquest.com/docview/3076019796
https://www.proquest.com/docview/3153729081
Volume 38
WOSCitedRecordID wos001262151500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1099-1573
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009204
  issn: 0951-418X
  databaseCode: DRFUL
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB60injxUV_1xQpSL8a2u9tkc_RVPKgUqdBb2OxuoKCpNK3Qmz_B3-gvcTZJU8UHgqeQZBKG3ZnMN9nZbwAOMegr7Srm-IyHDueSOVJI7nhKNl3RlCJsyrTZhHd7K7pdv51XVdq9MBk_RPHDzXpG-r22Di7DpDYlDX0aDk4QGzdnYY6i2fISzF3cte6vp5S7NG0emDaS5w3RnVDP1mlt8uznYPQFYX4GrGnEaS3_R9cVWMpxJjnNDGMVZkxchvmzPmLBcRkWbvIl9TJU2xl59fiYdKZ7sZJjUiXtKa31eA3OzkcDNXrsxUTGmsQy7r-9vKri2oeFcILnRRV1TxGdM3wm63DfuuycXzl5BwZHMUwdHYz_SvqcSeZFgka-0Q3taurq0DCPhlzWIxGFtokuxnnMPIRhituGPmEDbaMu2QaU4n5stoBoypRRRmN0xAwUJTxmIkZDYynoXe1X4GgyFYHK6cltl4yHICNWpgEOYmAHsQIHheRTRsnxjczuZDaD3CmTgKFJUB8zNIqvKG6jO9k1Ehmb_sjK2CIh3_PdX2QwSmBOgmCqApuZpRSKIP5DTOeKClRTg_hRw6DdubPH7b8K7sAiRUCVFR_uQmk4GJk9mFfPw14y2IdZryv2cxd4BxmECiM
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bTttAEB1BQMBLWwK0aaEsEgovGJLdtb1Wn8olAhGiCAUpb9Z6dy1FAgflgpS3fkK_sV_SWd9SVEBIPFm2x9ZqPeM5s5dzAPYx6SvtKeYEjEcO55I5Ukju-Eq6nnCliFyZik34nY7o94PuAvwo9sJk_BDlgJuNjPR_bQPcDkgfz1lDHyajIwTH7iIscfQitwJLZzet2_acc5em6oGpkjxvin7BPdugx8WzT7PRfxDzKWJNU07r47sa-wk-5EiT_MxcYx0WTFKF5ZMhosFZFVau80n1KtS7GX317JD05ruxxoekTrpzYuvZBpycTkdqej9IiEw0SWQy_PPrtyqv_TMVTvC8XEc9UETnHJ_jTbhtnfdOL5xcg8FRDItHBxGAkgFnkvmxoHFgdFN7mno6MsynEZeNWMSRldHFTI-1hzBMcSvpEzXROxqSbUElGSbmCxBNmTLKaMyPWIOihc9MzGhkLAm9p4MaHBTfIlQ5QbnVybgLM2plGmInhrYTa7BXWj5kpBzP2GwXnzPMw3IcMvQJGmCNRvEV5W0MKDtLIhMznFobu0wo8APvFRvME1iVIJyqwefMVcqGIAJEVOeJGtRTj3ixhWG3d2OPX99quAurF73rdti-7Fx9gzWK8CpbirgNlcloanZgWT1OBuPR9zwS_gK3cg0r
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFD4aWzXthUGBUTbASKi8LFtrO4mtPbGVCkSpoqqT-hY5tiNVgrTqBalv-wn7jfySHedWJi5C4ilKchJZ9jk534nt7wN4i0lfm0AzTzKeeJwr5imhuBdq5QfCVyLxVS42EQ6HYjKR0Q5cVHthCn6I-oebi4z8e-0C3M5Ner5lDZ2vFmcIjv0HsMd9GWBU7vVG_evBlnOX5uqBuZI874pJxT3boefVs_ez0S8Q8z5izVNO__C_GvsIHpZIk7wvXOMx7NisCY3LGaLBTRP2v5ST6k1oRwV99eaUjLe7sZanpE2iLbH15glcXq0Xev1tmhGVGZKpbPbj5lbX136aCid4Xq-jnmpiSo7P5VO47n8YX330Sg0GTzMsHj1EAFpJzhQLU0FTaU3XBIYGJrEspAlXnVSkiZPRxUyPtYewTHMn6ZN00Ts6ij2D3WyW2edADGXaamswP2INihYhsymjiXUk9IGRLXhXjUWsS4Jyp5PxNS6olWmMnRi7TmzBm9pyXpBy_MbmpBrOuAzLZczQJ6jEGo3iK-rbGFBulkRldrZ2Nm6ZkAxl8BcbzBNYlSCcasFR4Sp1QxABIqoLRAvauUf8sYVxNB6544t_NXwN-1GvHw8-DT8fwwFFdFWsRDyB3dVibV9CQ39fTZeLV2Ug3AEwPgym
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Curcumin+and+nano%E2%80%90curcumin+applications+in+psychiatric+disorders&rft.jtitle=Phytotherapy+research&rft.au=Mohammadzadeh%2C+R&rft.au=Fathi%2C+M&rft.au=Pourseif%2C+M+M&rft.au=Omidi%2C+Y&rft.date=2024-08-01&rft.issn=0951-418X&rft.volume=38&rft.issue=8+p.4240-4260&rft.spage=4240&rft.epage=4260&rft_id=info:doi/10.1002%2Fptr.8265&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0951-418X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0951-418X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0951-418X&client=summon